Loading...
Market
Top revenue-generating mRNA vaccine for GSK in 2025?
2
Resolution / Starting Odds
COVID-19 vaccine • 33%
Flu vaccine • 33%
Other mRNA vaccines • 33%
GSK financial reports and earnings releases
Story
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Similar markets
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Vaccines • 25%
Equal Contribution • 25%
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%
Positive • 33%
Neutral • 33%
Negative • 33%
COVID-19 vaccines • 25%
RSV vaccines • 25%
Other vaccines • 25%
Non-vaccine products • 25%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Both equally • 25%
Neither • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%